Neurocrine’s ingrezza shows efficacy in tardive dyskinesia

Neurocrine (NBIX) announced new data from a post-hoc analysis of the Phase 4 KINECT-PRO open-label study confirming that robust rates of symptomatic remission of tardive dyskinesia were achieved with once-daily ingrezza capsules. The analysis also showed sustained improvements in patient-reported outcomes among participants who achieved symptomatic remission. These results were presented at Psych Congress 2025 in San Diego. The post-hoc analysis of KINECT-PRO data included patients with mild to severe tardive dyskinesia severity and awareness with mild to severe associated distress, as measured by the Abnormal Involuntary Movement Scale items 8 and 10 at baseline. At Week 24, 26 of 45 patients achieved the remission threshold. Among patients meeting the symptomatic remission threshold, changes from baseline were evaluated in three validated patient-reported outcomes. After 24 weeks of treatment with ingrezza, these results demonstrated robust and sustained improvements in TD impact, functional impairment and HRQoL.